SARS-related warning letter
This article was originally published in The Tan Sheet
FDA issued a warning letter for claims that BetaLoe Immune System Defense Supplement provides "protection for defense against flu, SARS and anthrax," in addition to statements alluding to diseases. Statements include: "Why would a person want to use BetaLoe? Look around you...SARS outbreaks, deadly flu outbreaks, anthrax threats..." The agency says the claims render the product a drug, which requires an NDA...
You may also be interested in...
The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.
The documents issued by the US agency on 29 September set slightly different accuracy standards, reflecting the increased fragility of hospital patients.
The US FDA commissioner published a blog post commending and highlighting the work device center staff have done during the pandemic to speed tests and devices to market to save lives.